Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010)

Published in 2020 by Andrew M. Wardley, Lucy Kilburn

, Sarah Kernaghan, Iain Macpherson, Richard D. Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy P. Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew C. Winter, Belinda Kingston, Katie Wilkinson, Judith Bliss and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload